Naratriptan Akut Al

Naratriptan, the active ingredient in Naratriptan Akut Al, is a triptan presented as an oral tablet for oral use. It treats acute migraine attacks in adults.

GNH USA supplies Naratriptan Akut Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan is a triptan indicated for the acute treatment of migraine.

- Migraine (any type): provides rapid relief of headache pain and associated symptoms when taken at the onset of an attack. - Migraine without aura: reduces the intensity and duration of headache episodes without aura. - Migraine with aura: alleviates pain and may lessen the severity of aura manifestations.

Common Side Effects: - Chest discomfort or tightness - Nausea or vomiting - Dizziness or light‑headedness - Tingling or numbness in the extremities - Fatigue or drowsiness - Dry mouth

Serious or Rare Side Effects: - Serotonin syndrome, especially when combined with serotonergic agents - Coronary artery vasospasm leading to chest pain or myocardial ischemia - Severe allergic reactions such as anaphylaxis or angioedema - Persistent or worsening headache (rebound headache) - Hypertensive crisis in susceptible individuals - Rare cases of visual disturbances or loss of vision

Before using Naratriptan, consider the following precautions: - Cardiovascular disease: avoid use in patients with coronary artery disease, angina, or recent myocardial infarction. - Uncontrolled hypertension: contraindicated in patients with severe high blood pressure. - History of stroke or transient ischemic attack: use only after careful risk assessment. - Concomitant serotonergic drugs: monitor for signs of serotonin syndrome. - Pregnancy and lactation: safety not established; discuss risks with a healthcare professional. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Naratriptan may interact with several medication classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): avoid concurrent use due to serotonin toxicity. - Ergot alkaloids (e.g., ergotamine): combined vasoconstriction can cause severe cardiovascular events.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may elevate plasma levels of naratriptan, requiring dose adjustment. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can increase naratriptan exposure. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effectiveness.